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Cell self-renewal and the capacity to differentiate into multiple cell types (pluripotency) are biological attributes casting stem cells as attractive candidates for development of therapies targeting indications that involve functional restoration of damaged tissues. In the United States, clinical trials designed to demonstrate the safety and effectiveness of stem cell-based products are regulated by the U.S. Food and Drug Administration (FDA). To ensure that subjects enrolled in a clinical study involving stem cell-based products are not exposed to significant and unreasonable risk, the FDA reviews medical and scientific information that encompasses delineation of product-specific characteristics and preclinical testing to determine whether there is sufficient safety assurance to permit initiation of human clinical studies. E valuating the safety profile of an investigational stem cell-based product intended for clinical study within the United States is the responsibility of the U.S. Food and Drug Administration (FDA) (1) . FDA has more than two decades of experience regulating cellular therapies, including stem cell-based products, gained through evaluation of proposals to perform clinical trials, conducting of intramural research, participation in scientific workshops and symposiums, and convening of advisory committee meetings on the topic of stem cells. To determine whether it is reasonable to grant permission for a clinical trial to proceed, FDA evaluates potential risk based on results derived from analytical assessment of product characteristics as well as preclinical proofof-concept and safety testing, which, collectively, are considered within the context of a proposed clinical study (2) . From a regulatory perspective, FDA considers stem cell-based products to be somatic cellular therapies that do not warrant a distinct regulatory approach. In contrast to therapies composed of differentiated, lineage-restricted somatic cells, some stem cell-based products are capable of cell self-renewal and differentiation into multiple types of specialized cells. Due to the extent of their proliferative and differentiation potential, there is a spectrum of safety concerns that relate to a specific stem cell-based product.
Clinical studies involving investigational stem cell-based products, which may include one or more of a variety of stem cell types derived from various physiologic sources, have been submitted to FDA for review. Embryonic stem (ES) cells with their potential for limitless self-renewal and the capacity to give rise to all differentiated cell types within the body raise a specific set of questions related to the safety of stem cell-based products. Pluripotency of undifferentiated ES cells demonstrated by spontaneous formation of teratomalike masses composed of differentiated cells from the three somatic germ layers after injection in adult, immunodeficient mice (3, 4) requires the attention of preclinical testing. FDA review experience involving stem cell-based products that includes strategies to enrich the target cell population indicates it is likely that some small but detectable proportion of undifferentiated ES cells with the potential to form a teratoma will remain in cellular products that result from differentiation of ES cells. Although these are classified histologically as benign, it is important to evaluate the teratoma-forming potential of differentiated cellular products derived from ES cells, because the appearance of a teratoma in an anatomically sensitive location such as the central nervous system, joint capsule, or myocardium could pose a considerable safety concern.
Other safety issues germane to stem cellbased products include the potential for spontaneous malignant transformation due to protracted, ex vivo culture expansion (5), a propensity for cells to migrate from the original site of administration, development of immunogenicity resulting from eventual expression of the cell/tissue donor human leukocyte antigen molecules (6) , and the biologic impact of nontarget cellular impurities within the differentiated cell product.
The advent of induced pluripotent stem (iPS) cells generated by reprogramming of nonpluripotent, differentiated, adult somatic cells (7-9) has kindled interest in the possible use of such cells to generate autologous cellular products. The specific cellular reprogramming process selected for generating an iPS cell line may present novel risks for use of cellular products derived from that cell line requiring evaluation that involves both detailed product characterization and preclinical testing to support a proposed clinical use. At this time, reports describing new reprogramming methodologies are appearing in the scientific literature at a rapid pace; thus, additional safety issues that may need to be addressed remain to be fully delineated.
Safety assurance is achieved, in part, through comprehensive characterization of stem cell-based products. Because of the biological complexity exemplified by cellular composition heterogeneity, FDA suggests a multiparametric testing approach for characterization of stem cell-based products. This involves development of quantitative analytical techniques for conducting a panel of tests such as morphologic evaluation, detection of phenotype-specific cell surface antigens, assessment of unique biochemical markers, and genomic/proteomic analysis. In addition to relying on tests that target cell types within a stem cell-based product possessing desirable attributes, it is of equal importance to establish a panel of analytical tests that permits assessment of the cellular impurities profile. For example, analytical tests with sufficient sensitivity to detect discrete populations of cells with unwanted features are important when performing an impurities profile analysis of a cellular product derived from human embryonic stem cells. Testing could include detection of biomarkers for undifferentiated stem cells that have been linked with tumorigenesis. With respect to spontaneous transformation resulting from extended ex vivo cell culture, karyotypic analysis, routine evaluation of in vitro cell growth kinetics, and assessment of differentiation potential represent examples of tests that may be useful for detection of accumulating anomalies within a cell culture and may allow for establishment of parametric constraints on the cell expansion process. Undoubtedly, continued research efforts in cellular, molecular, and developmental biology will identify additional markers of value as well as improve on the specificity and sensitivity of tests used to characterize stem cell-based products. Given the potential for heterogeneity that results from multiple states of differentiation and/or cell lineages present within a single stem cell-based product, developing test methods that identify unique characteristics capable of anticipating clinical effectiveness poses further challenges.
Additional safety information pertaining to a stem cell-based product may be provided by execution of rigorous, well-designed studies conducted in appropriately sensitive preclinical experimental systems. Because cellular therapies are not readily retrievable once administered, the principles of conventional pharmacokinetics, namely, absorption, distribution metabolism, and excretion, are not applicable.
There are a number of important elements to consider when designing preclinical animal studies. They include (i) selection of relevant disease/injury models, (ii) testing of the product intended for clinical administration, (iii) using a route and method of delivery comparable to what is planned clinically, (iv) optimal timing of product adminis-tration with respect to disease/injury onset, and (v) an appropriate study duration that permits simultaneous assessment of potential adverse safety events and provides evidence of durable biological activity. Observable changes in animal behavior, physiologic function, and tissue morphology serve as indicators of cell survival and engraftment after administration, further in vivo cellular differentiation, physiologic integration, unchecked proliferation, migration to nontarget sites, ectopic tissue formation due to cell type impurities, and tumorigenesis (Fig. 1) .
When extrapolating preclinical testing results to the intended clinical setting, it is important to recognize and appreciate both the relevant attributes and the limitations of a selected animal model of disease/injury. In those circumstances when well-developed animal models of injury/ disease are available, evidence for robust proofof-concept preclinical test results is valuable and informative, particularly in situations when the targeted clinical indication calls for administration of the stem cell-based product into a highly vulnerable anatomic site such as the central nervous system, a joint capsule, or the myocardium.
Additional challenges posed by immunological discordance encountered when testing human stem cell-based products in preclinical animal models of disease are an important consideration. Obtaining meaningful information pertaining to safety and biological activity derived from preclinical testing of human stem cell-based products necessitates immunocompetence modification of the animal disease model. Moreover, if use of an immunosuppressive regimen during execution of the clinical study is contemplated to support engraftment of the investigational stem cell-based product, this fact is to be taken into account during the preclinical testing stage of the product's development.
Efforts are under way at FDA to promote communication and exchange of scientific information between the agency and its stakeholders, with the goal of facilitating development of safe and effective stem cell-based products. To achieve this objective, several mechanisms are under consideration, including FDA-led translational science workshops and establishment of collaborative partnerships with the stem cell research community. The acquisition of additional analytical tools to enable elucidation of product characteristics, creation of new animal-based or in vitro preclinical models that recapitulate human disease conditions with greater fidelity, and development of noninvasive imaging methodologies with sufficient sensitivity to monitor migration and ectopic tissue formation after administration (10) will require cooperative interdisciplinary efforts that involve the broader research community and serve to ensure further patient safety. 
